Digital Edition

AHA presents guidelines for managing manifestations of VTE

There are several therapies in addition to blood thinners that physicians should consider when managing patients with deep vein thrombosis, according to a new scientific statement from the American Heart Association. The statement is published online in Circulation. Read full article.

To confirm your e-newsletter subscription, click here.

To ensure future delivery of email newsletters from
Drug Topics, please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Anticoagulation Update

A monthly review of the
peer-reviewed literature by
Drug Topics' Editorial Advisor
Anna D. Garrett, PharmD, BCPS. Anna Garrett is manager, Outpatient Clinical Pharmacy Programs, Mission Hospital, Asheville, N.C.

CHA₂DS₂-VASc score tops CHADS₂ as better thromboembolism determinant Read full article.

Monitoring ABP helps identify true resistant hypertension

Ambulatory blood-pressure monitoring is a useful diagnostic tool for differentiating between true and "white-coat resistant" hypertension (blood pressure that spikes in the doctor's office), reported a study published online in Hypertension. Read full article.

Vaginal progesterone gel reduces rate of preterm birth

Vaginal progesterone administered from the mid-trimester of pregnancy until term in women with a premature cervical shortening, as confirmed by transvaginal ultrasound, significantly reduced the rate of preterm birth before 33 weeks gestation, according to a phase 3 study published online in Ultrasound in Obstetrics & Gynecology. Read full article.

FDA approves Sylatron for adjuvant treatment of melanoma

FDA has approved peginterferon alfa-2b (Sylatron, Merck) for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days
of definitive surgical resection including complete lymphadenectomy. Read full article.

FDA approves rituximab to treat rare disorders

FDA has approved rituximab (Rituxan, Genentech and Biogen Idec) in combination with glucocorticosteroids for the treatment of 2 forms of anti-neutrophil cytoplasmic antibody-associated vasculitis, with Wegener¹s granulomatosis and microscopic polyangiitis. Read full article.

BPS approves ambulatory care designation; explores new specialties

The Board of Pharmacy Specialties announced at its April meeting that the official designation for pharmacists who pass the ambulatory care pharmacy specialty certification exam would be Board Certified Ambulatory Care Pharmacist. These pharmacists will carry the designation BCACP. Read full article.

Meetings and Events

April 27-30, 2011 AMCP's 23rd Annual Meeting & Showcase
Minneapolis, MN
Contact:
100 North Pitt Street Suite 400
Alexandria, VA 22314
800-827-2627; 703-683-8416

April 30-May 3, 2011 NACDS Annual Meeting
Scottsdale, AZ
Contact:
P.O. Box 34814
Alexandria, Virginia 22334-0814
703-837-4300

May 17-19, 2011 ASCP Spring Conference + Exhibition (formerly known as the ASCP Midyear Conference)
Las Vegas, Nevada
Contact:
Alexandria, VA 22314
Phone: 703-739-1300 or 800-355-2727
Fax: 703-739-1321 or 800-220-1321
info@ascp.com

May 23-25, 2011 NCPA Legislative Conference
Washington, DC
Contact:
100 Daingerfield Road
Alexandria, VA 22314
800-544-7447

June 1-2, 2011 PQA Annual Meeting
Washington, DC
Contact:
Karen Peterson
9687 South Run Oaks Drive
Fairfax Station, VA 22039
Fax: 703-690-1756
kpeterson@pqaalliance.org

June 2-3 PQA/URAC Medication Adherence Summit
Washington, DC
Contact:
Jackie Green
1220 L Street NW, Suite 400
Washington, DC 20005
703-927-1599
jgreen@pqaalliance.org

Connect to Us

Contact a Drug Topics editor Click Here
Contact a Drug Topics sales representative Click Here
Learn about direct mail, reprints and classifieds in Drug Topics Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.